Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11025555 | 1.00 | APLNR (0.34) | APLNRHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11886485 | 0.77 | CYP2D6 (0.35) | APLNRHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11913740 | 0.77 | CYP2D6 (0.35) | APLNRHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11025847 | 0.77 | TSHR (0.31) | — | |
| SCHEMBL11027378 | 0.77 | TSHR (0.31) | — | |
| SCHEMBL11949370 | 0.77 | APLNR (0.34) | APLNRHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11301796 | 0.77 | APLNR (0.34) | APLNRHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL15835735 | 0.75 | HDAC3 (0.33) | APLNRHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL15835722 | 0.75 | HDAC3 (0.33) | APLNRHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11302632 | 0.75 | APLNR (0.32) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665732-B1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-9139594-B2 | Fused aminodihydropyrimidone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-9079914-B2 | Fused aminodihydro-oxazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| EP-2653473-A1 | Fused Aminodihydro-Oxazine Derivatives | Eisai R&D Management Co., Ltd. (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2456774-B1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20130203740-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20130203740-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8338407-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338407-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| WO-2012098213-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| WO-2011009897-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009898-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | APLNR 691/4885HDAC3 1903/4885HDAC1 504/4885 |
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | BACE1, APP, BACE2 | APLNR 1184/4885HDAC3 1633/4885HDAC1 345/4885 |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | APLNR 691/4885HDAC3 1903/4885HDAC1 504/4885 |
| US-20130203740-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | APLNR 691/4885HDAC3 1903/4885HDAC1 504/4885 |
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | BACE1, APP, BACE2 | APLNR 1853/4885HDAC3 1846/4885HDAC1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.